Timothy Junius Triche
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Timothy Junius Triche has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
Ching C. Lau
Departments of Pediatrics, Texas Children's Cancer Center; Departments of 2 Pathology and
4 shared publicationsJaya Visvanathan
4 shared publications- Jeffrey Clark Murray
University of Iowa
4 shared publications - Jianhe Shen
Fujian Normal University
4 shared publications - Kwong-Kwok Wong
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
4 shared publications - Laszlo Perlaky
Departments of Pediatrics, Texas Children's Cancer Center; Departments of 2 Pathology and
4 shared publications
Latest Publications
- Open Access
Targeted Nanoparticles: an Innovative Modality in the Treatment of Cancer
Despite progress made in the development of anticancer therapeutics, traditional small-molecule chemotherapeutics often struggle to overcome toxicity, efficacy, and off-target effects. These specific issues can be overcome by either encapsulating the drug or by targeting it directly to the tumor cell. Here, we describe a novel targeted nanoparticle (referred to as a nano-antibody-drug conjugate Targeted Nanosphere or nADC/TNS), based cancer therapeutic platform that can improve the efficacy of a broad range of existing therapeutics. Targeting is antibody-directed, as with antibody-drug conjugates (ADCs). Still, the payload per antibody is vastly greater by orders of magnitude (a thousand for nADC/TNS versus two to eight for ADCs). The nADC/TNS consists of an approximately 80 nm drug-filled nanoparticle composed of phospholipids, cholesterol, and UV cross-linkable diacetylene lipids. We describe the preparation, characterization, and evaluation of nADC/TNS as a novel, versatile, and effective treatment modality for cancer and potentially other diseases. This report focuses on data with nADC/TNS variants NV101 (anti-CD99 targeted, doxorubicin-filled), NV102 (anti-CD19 targeted, doxorubicin-filled), and NV103 (anti-CD99 targeted, irinotecan-filled). We investigated NV101 and NV103 in a mouse model with implanted and metastatic Ewing tumors (ES). NV101 demonstrated significant tumor burden reduction while NV103 induced complete ablation of ES tumors. NV102 demonstrated complete ablation of chemotherapy-resistant relapsed adult lymphocytic leukemia (ALL). These results document the potential superior efficacy of antibody-targeted nanoparticles containing a variety of small-molecule payloads, compared to their free molecule equivalents.
Open AccessTargeted Nanoparticles: an Innovative Modality in the Treatment of Cancer
Despite progress made in the development of anticancer therapeutics, traditional small-molecule chemotherapeutics often struggle to overcome toxicity, efficacy, and off-target effects. These specific issues can be overcome by either encapsulating the drug or by targeting it directly to the tumor cell. Here, we describe a novel targeted nanoparticle (referred to as a nano-antibody-drug conjugate Targeted Nanosphere or nADC/TNS), based cancer therapeutic platform that can improve the efficacy of a broad range of existing therapeutics. Targeting is antibody-directed, as with antibody-drug conjugates (ADCs). Still, the payload per antibody is vastly greater by orders of magnitude (a thousand for nADC/TNS versus two to eight for ADCs). The nADC/TNS consists of an approximately 80 nm drug-filled nanoparticle composed of phospholipids, cholesterol, and UV cross-linkable diacetylene lipids. We describe the preparation, characterization, and evaluation of nADC/TNS as a novel, versatile, and effective treatment modality for cancer and potentially other diseases. This report focuses on data with nADC/TNS variants NV101 (anti-CD99 targeted, doxorubicin-filled), NV102 (anti-CD19 targeted, doxorubicin-filled), and NV103 (anti-CD99 targeted, irinotecan-filled). We investigated NV101 and NV103 in a mouse model with implanted and metastatic Ewing tumors (ES). NV101 demonstrated significant tumor burden reduction while NV103 induced complete ablation of ES tumors. NV102 demonstrated complete ablation of chemotherapy-resistant relapsed adult lymphocytic leukemia (ALL). These results document the potential superior efficacy of antibody-targeted nanoparticles containing a variety of small-molecule payloads, compared to their free molecule equivalents.
- Open Access
EZH2-driven immune evasion at disease presentation defines a targetable high-risk subset of acute leukemia exemplified by t(16;21) FUS::ERG AML
The past 25 years of clinical trials have produced few improvements in pediatric AML (pAML) outcomes. This is acutely evident in patients with t(16;21)(p11;q22), yielding FUS::ERG . Patients with FUS::ERG -positive AML relapse quickly and do not respond to transplantation. Major histocompatibility complex (MHC) class I & II receptors and costimulatory molecules are absent at diagnosis in FUS::ERG- positive AML, mirroring the phenotype and outcomes of post-transplant relapse. We show that this is driven by overexpression of EZH2, in vitro and in multiple clinical cohorts. While FUS::ERG AML is the most extreme example, this phenotype is shared by lethal CBFA2T3::GLIS2- driven AML, and patients with RUNX1::RUNX1T1 have significantly worse outcomes when EZH2 overexpression co-occurs. The FDA-approved EZH2 inhibitor tazemetostat reverses this phenotype, re-establishes MHC presentation, and elicits immune effector cell-mediated elimination. EZH2 inhibitors may provide the first targeted therapeutic frontline option for AML patients with FUS::ERG , with the potential for broader frontline immunostimulatory benefits. STATEMENT OF SIGNIFICANCE: Here we show an immune-evasive phenotype, present at diagnosis and characterized by elevated EZH2 levels and loss of MHC class I and II, defines a high-risk subtype of acute leukemia. Treatment with the EZH2 inhibitor tazemetostat and IFN-γ reverses this phenotype and results in immune cell engagement and blast elimination.
Open AccessEZH2-driven immune evasion at disease presentation defines a targetable high-risk subset of acute leukemia exemplified by t(16;21) FUS::ERG AML
The past 25 years of clinical trials have produced few improvements in pediatric AML (pAML) outcomes. This is acutely evident in patients with t(16;21)(p11;q22), yielding FUS::ERG . Patients with FUS::ERG -positive AML relapse quickly and do not respond to transplantation. Major histocompatibility complex (MHC) class I & II receptors and costimulatory molecules are absent at diagnosis in FUS::ERG- positive AML, mirroring the phenotype and outcomes of post-transplant relapse. We show that this is driven by overexpression of EZH2, in vitro and in multiple clinical cohorts. While FUS::ERG AML is the most extreme example, this phenotype is shared by lethal CBFA2T3::GLIS2- driven AML, and patients with RUNX1::RUNX1T1 have significantly worse outcomes when EZH2 overexpression co-occurs. The FDA-approved EZH2 inhibitor tazemetostat reverses this phenotype, re-establishes MHC presentation, and elicits immune effector cell-mediated elimination. EZH2 inhibitors may provide the first targeted therapeutic frontline option for AML patients with FUS::ERG , with the potential for broader frontline immunostimulatory benefits. STATEMENT OF SIGNIFICANCE: Here we show an immune-evasive phenotype, present at diagnosis and characterized by elevated EZH2 levels and loss of MHC class I and II, defines a high-risk subtype of acute leukemia. Treatment with the EZH2 inhibitor tazemetostat and IFN-γ reverses this phenotype and results in immune cell engagement and blast elimination.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from TDP1 and PARP1 Deficiency Are Cytotoxic to Rhabdomyosarcoma Cells
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from TDP1 and PARP1 Deficiency Are Cytotoxic to Rhabdomyosarcoma Cells
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from TDP1 and PARP1 Deficiency Are Cytotoxic to Rhabdomyosarcoma Cells
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from TDP1 and PARP1 Deficiency Are Cytotoxic to Rhabdomyosarcoma Cells
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Expression Profiles of Osteosarcoma That Can Predict Response to Chemotherapy
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Expression Profiles of Osteosarcoma That Can Predict Response to Chemotherapy
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Expression Profiles of Osteosarcoma That Can Predict Response to Chemotherapy
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Expression Profiles of Osteosarcoma That Can Predict Response to Chemotherapy
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 & Table S1 from Expression Profiles of Osteosarcoma That Can Predict Response to Chemotherapy
Supplementary Figure S1 & Table S1 from Expression Profiles of Osteosarcoma That Can Predict Response to Chemotherapy
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 & Table S1 from Expression Profiles of Osteosarcoma That Can Predict Response to Chemotherapy
Supplementary Figure S1 & Table S1 from Expression Profiles of Osteosarcoma That Can Predict Response to Chemotherapy